The B4GALT1 Knockout A-549 Polyclonal Cells are a genetically modified human cell population generated by CRISPR/Cas9-mediated target-gene disruption, eliminating functional expression of the B4GALT1 gene in the A-549 lung carcinoma background. This polyclonal knockout cell product provides a heterogeneous knockout pool, enabling robust loss-of-function studies without clonal selection artifacts. The cells are designed for researchers investigating the roles of beta-1,4-galactosyltransferase 1 in glycosylation-related cellular processes, particularly within the context of lung adenocarcinoma biology. These ready-to-use polyclonal knockout cells serve as a foundational model for interrogating the consequences of ablated galactosylation on glycoprotein structures and downstream signaling networks.
The parental A-549 cell line was originally derived from the lung carcinoma tissue of a 58-year-old Caucasian male with lung adenocarcinoma. These cells exhibit epithelial morphology and harbor a KRAS G12S activating mutation while retaining wild-type p53 status, reflecting a clinically relevant oncogenic background. As alveolar basal epithelial cells, A-549 cultures are a widely employed model for studying human lung adenocarcinoma, including mechanisms of tumor progression, drug response, and epithelial-mesenchymal transition. The availability of a B4GALT1 knockout in this well-characterized line allows direct examination of glycosylation alterations in a defined cancer genotype, facilitating comparisons with wild-type A-549 controls.
B4GALT1 encodes a type II membrane-bound glycosyltransferase that catalyzes the transfer of galactose from UDP-galactose to terminal N-acetylglucosamine residues on glycoproteins and glycolipids, forming the Gal(??1-4)GlcNAc disaccharide moiety. This enzyme is a central component of N-glycan and O-glycan biosynthesis, glycosphingolipid metabolism, and, in the mammary gland, lactose synthesis where it functions in a complex with alpha-lactalbumin. In the signaling context, B4GALT1 is transcriptionally regulated downstream of prolactin receptor and STAT5 activation, and its activity directly generates galactosylated glycoconjugates that decorate cell surface receptors, adhesion molecules, and secreted proteins. The enzyme interacts with UDP-galactose and diverse glycoprotein substrates, and its products are recognized by galectins and other glycan-binding proteins, thereby influencing cell adhesion, migration, and immune surveillance.
Disruption of B4GALT1 in A-549 cells is expected to profoundly alter the cellular glycome, eliminating a major ??1-4-linked galactose modification on N-glycans and glycosphingolipids. Given the role of aberrant glycosylation in cancer??including altered expression of ??1-4-galactosyltransferases in lung malignancies??this knockout model provides a relevant tool to dissect how specific glycan epitopes contribute to tumorigenic phenotypes. In the A-549 background with active KRAS signaling, loss of terminal galactosylation may affect growth factor receptor activation, integrin-mediated attachment, and evasion of apoptosis, offering insights into the intersection of oncogenic pathways and glycosylation. The model also permits investigation of how B4GALT1 deficiency impacts the production of cancer-associated glycan antigens such as sialyl-Lewis X and their roles in metastasis.
Researchers can employ the B4GALT1 Knockout A-549 Polyclonal Cells in a variety of glycobiology-focused applications, including glycoengineering studies to define glycosylation-dependent functions, screens for glycosylation-modifying drugs, and biomarker discovery efforts using comparative glycomics. Typical experimental workflows include lectin blotting (e.g., RCA-I for terminal galactose), flow cytometry with galactose-specific lectins, glycan mass spectrometry for structural profiling, cell adhesion assays on extracellular matrix components, and phospho-array analysis of signaling pathways downstream of glycosylated receptors. These knockout cells are also suitable for co-culture experiments to examine immune cell recognition or for xenograft studies evaluating the role of host-cell glycosylation in tumor growth. For further technical details, pricing, and availability, please contact Ascent Research.
